ATE431551T1 - Marker für entzündungszustände - Google Patents

Marker für entzündungszustände

Info

Publication number
ATE431551T1
ATE431551T1 AT02707438T AT02707438T ATE431551T1 AT E431551 T1 ATE431551 T1 AT E431551T1 AT 02707438 T AT02707438 T AT 02707438T AT 02707438 T AT02707438 T AT 02707438T AT E431551 T1 ATE431551 T1 AT E431551T1
Authority
AT
Austria
Prior art keywords
inflammatory conditions
markers
pregnancy
marker
plasma protein
Prior art date
Application number
AT02707438T
Other languages
English (en)
Inventor
Cheryl Conover
Antonio Bayes-Genis
Holmes, Jr
Robert Schwartz
Original Assignee
Mayo Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation filed Critical Mayo Foundation
Application granted granted Critical
Publication of ATE431551T1 publication Critical patent/ATE431551T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)
  • Organic Chemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Rehabilitation Therapy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Nuclear Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT02707438T 2001-01-12 2002-01-11 Marker für entzündungszustände ATE431551T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/760,376 US6500630B2 (en) 2001-01-12 2001-01-12 Marker for inflammatory conditions
PCT/US2002/000762 WO2002056015A1 (en) 2001-01-12 2002-01-11 Marker for inflammatory conditions

Publications (1)

Publication Number Publication Date
ATE431551T1 true ATE431551T1 (de) 2009-05-15

Family

ID=25058918

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02707438T ATE431551T1 (de) 2001-01-12 2002-01-11 Marker für entzündungszustände

Country Status (11)

Country Link
US (9) US6500630B2 (de)
EP (2) EP1350109B1 (de)
JP (3) JP4338972B2 (de)
AT (1) ATE431551T1 (de)
AU (1) AU2002241845B2 (de)
CA (1) CA2434512C (de)
DE (1) DE60232303D1 (de)
DK (1) DK1350109T3 (de)
ES (1) ES2324767T3 (de)
PT (1) PT1350109E (de)
WO (1) WO2002056015A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002210403A1 (en) * 2000-10-20 2002-04-29 Como Biotech Aps Pregnancy-associated plasma protein-a2 (papp-a2)
US6500630B2 (en) * 2001-01-12 2002-12-31 Mayo Foundation For Medical Education And Research Marker for inflammatory conditions
ATE261126T1 (de) * 2002-08-01 2004-03-15 Mtm Lab Ag Verfahren für lösung-basierte diagnose
CA2509063C (en) * 2002-11-16 2010-11-02 Dade Behring Marburg Gmbh Scd40l and placental growth factor (plgf) as biochemical marker combinations in cardiovascular diseases
EP1530047A1 (de) * 2003-11-07 2005-05-11 Roche Diagnostics GmbH Proximale Markermoleküle der Arterienthrombose und der Entzündung zur Risikostratifizierung einer koronaren Herzkrankheit
WO2005064307A2 (en) * 2003-12-23 2005-07-14 Roche Diagnostics Gmbh Method of assessing rheumatoid arthritis by measuring anti-ccp and interleukin 6
CN1934449A (zh) * 2004-01-28 2007-03-21 图尔库大学 用于诊断急性冠状动脉综合征的改进的方法
WO2005078452A1 (en) * 2004-02-05 2005-08-25 Medtronic, Inc. Methods and apparatus for identifying patients at risk for life threatening arrhythmias
US7608458B2 (en) * 2004-02-05 2009-10-27 Medtronic, Inc. Identifying patients at risk for life threatening arrhythmias
US8335652B2 (en) * 2004-06-23 2012-12-18 Yougene Corp. Self-improving identification method
US8027791B2 (en) * 2004-06-23 2011-09-27 Medtronic, Inc. Self-improving classification system
US20050287574A1 (en) * 2004-06-23 2005-12-29 Medtronic, Inc. Genetic diagnostic method for SCD risk stratification
EP1904846A4 (de) * 2005-06-29 2009-03-18 Rules Based Medicine Inc Verfahren und kits zur diagnose von akutem koronarsyndrom
AU2006315274B2 (en) * 2005-11-17 2012-07-05 Biogen Ma Inc. Platelet aggregation assays
US20100310461A1 (en) * 2007-04-18 2010-12-09 Biochromix Pharma Ab Binding of pathological forms of proteins using conjugated polyelectrolytes
US20100310462A1 (en) * 2007-04-18 2010-12-09 Biochromix Ab Binding of pathological forms of proteins using conjugated polyelectrolytes
EP2017351B1 (de) * 2007-07-20 2010-10-27 Université de Liège Kombination aus Verfahren zur sequentiellen Messung (1.) der enzymatisch aktiven Fraktion und (2.) der Gesamtmenge eines Enzyms
US20110143956A1 (en) * 2007-11-14 2011-06-16 Medtronic, Inc. Diagnostic Kits and Methods for SCD or SCA Therapy Selection
US20090131276A1 (en) * 2007-11-14 2009-05-21 Medtronic, Inc. Diagnostic kits and methods for scd or sca therapy selection
US8125331B2 (en) 2008-08-27 2012-02-28 The Invention Science Fund I, Llc Health-related signaling via wearable items
US8284046B2 (en) 2008-08-27 2012-10-09 The Invention Science Fund I, Llc Health-related signaling via wearable items
US8094009B2 (en) 2008-08-27 2012-01-10 The Invention Science Fund I, Llc Health-related signaling via wearable items
US20100056873A1 (en) * 2008-08-27 2010-03-04 Allen Paul G Health-related signaling via wearable items
US8130095B2 (en) 2008-08-27 2012-03-06 The Invention Science Fund I, Llc Health-related signaling via wearable items
US20100081928A1 (en) * 2008-09-29 2010-04-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Histological Facilitation systems and methods
WO2010132546A2 (en) * 2009-05-12 2010-11-18 Medtronic, Inc. Sca risk stratification by predicting patient response to anti-arrhythmics
FI20095733A0 (fi) 2009-06-29 2009-06-29 Hytest Oy IGFBP-4-fragmenttien määrittäminen diagnostisena menetelmänä
EP2478371B1 (de) * 2009-09-17 2016-05-04 Roche Diagnostics GmbH Multimarker-Panel für Linksherzhypertrophie
FI20115367A0 (fi) 2011-04-15 2011-04-15 Hytest Oy Menetelmä sydän- ja verisuonitapahtumien määrittämiseksi käyttämällä IGFBP-fragmentteja
WO2013025904A1 (en) * 2011-08-16 2013-02-21 The General Hospital Corporation Apparatus, method and computer-accessible medium for determining antigen immunoreactivity in tissue
CN106460062A (zh) 2014-05-05 2017-02-22 美敦力公司 用于scd、crt、crt‑d或sca治疗识别和/或选择的方法和组合物
CA3012985A1 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
RU2646490C1 (ru) * 2016-09-16 2018-03-05 Гюзелия Хатыбулловна Каюмова Способ прогнозирования летальности у пациентов с инфарктом миокарда
US11519024B2 (en) * 2017-08-04 2022-12-06 Billiontoone, Inc. Homologous genomic regions for characterization associated with biological targets
US11646100B2 (en) 2017-08-04 2023-05-09 Billiontoone, Inc. Target-associated molecules for characterization associated with biological targets
KR102109850B1 (ko) * 2017-08-21 2020-05-13 한양대학교 산학협력단 염증의 유무 예측을 위한 바이오마커
EP3941523A4 (de) 2019-03-22 2022-12-28 Mayo Foundation for Medical Education and Research Materialien und verfahren zur behandlung von polyzystischer nierenerkrankung
WO2021062298A1 (en) 2019-09-27 2021-04-01 Arterez, Inc. Biomarker panel targeted to diseases due to multifactorial ontology of glycocalyx disruption
EP4619023A1 (de) 2022-11-15 2025-09-24 Calico Life Sciences LLC Anti-papp-a-antikörper und verfahren zur verwendung davon

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US525641A (en) * 1894-09-04 Weather-strip
US5039521A (en) * 1989-01-11 1991-08-13 Hyal Pharmaceutical Corporation Immune cell proliferation inhibitors
US5324502A (en) * 1992-04-02 1994-06-28 Purdue Research Foundation Radiopharmaceuticals for imaging the heart
AU5355094A (en) * 1992-10-14 1994-05-09 Sterling Winthrop Inc. Therapeutic and diagnostic imaging compositions and methods
WO1994021686A1 (en) * 1993-03-19 1994-09-29 Northern Sydney Area Health Service Papp-a, its immunodetection and uses
JPH11507046A (ja) * 1995-06-07 1999-06-22 イムノメディクス，インコーポレイテッド 診断剤および治療剤の標的部位への改良された送達方法
US6331286B1 (en) * 1998-12-21 2001-12-18 Photogen, Inc. Methods for high energy phototherapeutics
CA2272090A1 (en) 1996-12-09 1998-06-18 Matthew J. Fisher Integrin antagonists
WO1998043630A1 (en) 1997-04-02 1998-10-08 Brigham And Women's Hospital, Inc. Means of ascertaining an individual's risk profile for atherosclerotic disease
DE19757250A1 (de) 1997-12-22 1999-07-01 Forssmann Wolf Georg Prof Dr Insulin-like growth factor binding protein und seine Verwendung
CA2367360C (en) 1999-03-15 2011-08-09 Mayo Foundation For Medical Education And Research Insulin-like growth factor binding protein-4 protease
US7115382B1 (en) * 1999-03-15 2006-10-03 Mayo Foundation For Medical Education And Research Method for detecting IGFBP-4 protease without detecting IGFBP-4 protease/proMBP Complex
US6500630B2 (en) * 2001-01-12 2002-12-31 Mayo Foundation For Medical Education And Research Marker for inflammatory conditions
JP4251617B2 (ja) 2003-03-10 2009-04-08 キヤノン株式会社 電子機器
US20060063162A1 (en) * 2004-09-23 2006-03-23 Deng David X Biological marker for inflammation

Also Published As

Publication number Publication date
DE60232303D1 (de) 2009-06-25
US8323913B2 (en) 2012-12-04
WO2002056015A1 (en) 2002-07-18
ES2324767T3 (es) 2009-08-14
CA2434512C (en) 2010-05-11
US20070065879A1 (en) 2007-03-22
US20020132278A1 (en) 2002-09-19
EP1350109B1 (de) 2009-05-13
US7723049B2 (en) 2010-05-25
US20100285510A1 (en) 2010-11-11
US20090197342A1 (en) 2009-08-06
US20110212024A1 (en) 2011-09-01
JP4338972B2 (ja) 2009-10-07
US20040197844A1 (en) 2004-10-07
DK1350109T3 (da) 2009-08-31
US20050136498A1 (en) 2005-06-23
US7939280B2 (en) 2011-05-10
EP2081026A1 (de) 2009-07-22
JP2009198510A (ja) 2009-09-03
AU2002241845B2 (en) 2006-11-09
JP2004531696A (ja) 2004-10-14
US6500630B2 (en) 2002-12-31
EP1350109A4 (de) 2004-08-18
JP2010281833A (ja) 2010-12-16
PT1350109E (pt) 2009-06-30
US20030003521A1 (en) 2003-01-02
US6699675B2 (en) 2004-03-02
JP5226749B2 (ja) 2013-07-03
CA2434512A1 (en) 2002-07-18
EP1350109A1 (de) 2003-10-08
US20060110773A1 (en) 2006-05-25
JP4610660B2 (ja) 2011-01-12

Similar Documents

Publication Publication Date Title
DK1350109T3 (da) Markör for betændelsestilstande
NO2022042I1 (no) Voclosporin, a calcineurin inhibitor, its salts and esters
ATE334703T1 (de) Zubereitung für restenoseprophylaxe
ATE304753T1 (de) Kodeleistungsmessung für dynamische kanalzuwendung
ATE286049T1 (de) Pyridazinonaldose reductase inhibitoren
DE60230934D1 (de) Fab-i-inhibitoren
DE60231401D1 (de) Für verstaubare sauerstoffmasken für flugzeugbesatzungen
DE60003779D1 (de) Einschaltgerät für Beleuchtung
DE60234125D1 (de) E inhibitoren
DE60231863D1 (de) Linearkompressor
DE60130520D1 (de) Lichtquelle
DE50113812D1 (de) Explosivstoffgetriebene RF-Strahlenquelle
DE60140929D1 (de) Immunoassay für HIV-Protease-Hemstoffe
DE60238019D1 (de) Übertragungswerkzeug für Beschichtungsfilm
FI20012460L (fi) Putkiston haarakappale
DE60129947D1 (de) Zusammensetzung für die lasermarkierung
DE60223967D1 (de) Pipettenmarkierungen
DE50113261D1 (de) Linearwälzlager
DE60203608D1 (de) Metallblöcke für bearbeitungsverwendungen
ATE535775T1 (de) Präzisionsdendrometer
BRPI0215849A2 (pt) inibidor de ferrugem
PL363840A1 (pl) Inhibitor absorpcji monoaminy
DE60303231D1 (de) Linearlagerung
DE60209970D1 (de) Metallsubstrat
DE60217480D1 (de) 17-METHYLEN-ANDROSTAN-3a-OL-ANALOGA ALS CRH- INHIBITOREN

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1350109

Country of ref document: EP